Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition
- 15 August 2007
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (16) , 8784-8792
- https://doi.org/10.1128/jvi.00552-07
Abstract
The mechanisms of human papillomavirus (HPV) neutralization by antibodies are incompletely understood. We have used HPV16 pseudovirus infection of HaCaT cells to analyze how several neutralizing monoclonal antibodies (MAbs) generated against HPV16 L1 interfere with the process of keratinocyte infection. HPV16 capsids normally bind to both the cell surface and extracellular matrix (ECM) of HaCaT cells. Surprisingly, two strongly neutralizing MAbs, V5 and E70, did not prevent attachment of capsids to the cell surface. However, they did block association with the ECM and prevented internalization of cell surface-bound capsids. In contrast, MAb U4 prevented binding to the cell surface but not to the ECM. The epitope recognized by U4 was inaccessible when virions were bound to the cell surface but became accessible after endocytosis, presumably coinciding with receptor detachment. Treatment of capsids with heparin, which is known to interfere with binding to cell surface heparan sulfate proteoglycans (HSPGs), also resulted in HPV16 localization to the ECM. These results suggest that the U4 epitope on the intercapsomeric C-terminal arm is likely to encompass the critical HSPG interaction residues for HPV16, while the V5 and E70 epitopes at the apex of the capsomer overlap the ECM-binding sites. We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes.Keywords
This publication has 70 references indexed in Scilit:
- Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particlesVirology, 2007
- Identification of Human Papillomavirus Type 16 L1 Surface Loops Required for Neutralization by Human SeraJournal of Virology, 2006
- Prophylactic human papillomavirus vaccinesJournal of Clinical Investigation, 2006
- Postentry Neutralization of Adenovirus Type 5 by an Antihexon AntibodyJournal of Virology, 2004
- Further Evidence that Papillomavirus Capsids Exist inTwo DistinctConformationsJournal of Virology, 2003
- Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter CellsJournal of Virology, 2003
- Molecular diversity of heparan sulfateJournal of Clinical Investigation, 2001
- Preparation of Extracellular Matrices Produced by Cultured Corneal Endothelial and PF‐HR9 Endodermal CellsCurrent Protocols in Cell Biology, 1999
- Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolutionJournal of Molecular Biology, 1998
- Antibodies that block virus attachment to vero cells are a major component of the human neutralizing antibody response against dengue virus type 2Journal of Medical Virology, 1995